The first patient has been enrolled in a phase 4 clinical trial to evaluate the safety and efficacy of Tepezza in patients with chronic thyroid eye disease, according to a press release from Horizon Therapeutics.
“It is common for patients who are in the chronic phase of the disease to continue having debilitating symptoms, like eye pain and bulging, that interfere with daily living and require treatment,” trial investigator Raymond Douglas, MD, PhD, said in the release. “In a number of published case reports and analyses, Tepezza improved thyroid eye (Read more...)